Risk of Intentional Self-Harm After GLP-1 RA Use Among Patients with Type 2 Diabetes in FDA’s Sentinel Distributed Database

This poster describes a project that assessed the association between glucagon-like peptide-1 receptor agonists (GLP-1 RA) use and intentional self-harm among a large cohort of health plan members with a diagnosis of type 2 diabetes mellitus in the United States. It was presented at the 2026 ISPE Annual Meeting.